Home » Stocks » OCGN

Ocugen, Inc. (OCGN)

Stock Price: $6.94 USD -0.14 (-1.98%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $7.07 +0.13 (1.87%) Jul 23, 7:59 PM
Market Cap 1.38B
Revenue (ttm) 42,620
Net Income (ttm) -37.50M
Shares Out 186.30M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE 2.96
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $6.94
Previous Close $7.08
Change ($) -0.14
Change (%) -1.98%
Day's Open 7.08
Day's Range 6.92 - 7.36
Day's Volume 10,251,547
52-Week Range 0.25 - 18.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - July 23, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and certain of i...

23 hours ago - Newsfile Corp

BENSALEM, Pa., July 23, 2021 /PRNewswire/ -- Law Offices of Howard G.

1 day ago - PRNewsWire

Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Info...

Other stocks mentioned: AFMD, GTBP
1 day ago - PennyStocks

It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete.

2 days ago - InvestorPlace

New York, New York--(Newsfile Corp. - July 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocug...

2 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 20, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that t...

4 days ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 202...

4 days ago - Newsfile Corp

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...

Other stocks mentioned: IMNM, MRNA, NRBO, NVAX, QDEL
4 days ago - InvestorPlace

LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Oc...

4 days ago - PRNewsWire

The delta variant is lifting the tide of companies associated with COVID testing and prevention.

5 days ago - The Motley Fool

NEW YORK, July 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and certain of its officers. Th...

1 week ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGEN).Shar...

1 week ago - Newsfile Corp

MALVERN, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness disease...

1 week ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - July 16, 2021) - WHY: New York, N.Y., July 16, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Ocugen, Inc. ("Ocugen") (NA...

1 week ago - Newsfile Corp

There won't be a market for COVAXIN in the US as vaccination rates continue moving up. Without a successful US launch of COVAXIN, OCGN stock doesn't even warrant the price of a dollar.

1 week ago - InvestorPlace

New York, New York--(Newsfile Corp. - July 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that th...

1 week ago - Newsfile Corp

We're taking a look at some of the lesser-known short-squeeze stocks popular with retail investors that should be on your radar. The post 9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investor...

Other stocks mentioned: ASO, BLNK, CARV, GDRX, GEO, MSTR, ROOT ...
1 week ago - InvestorPlace

San Diego, California--(Newsfile Corp. - July 15, 2021) - The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Ex...

1 week ago - Newsfile Corp

Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling submission of its regulatory...

1 week ago - Benzinga

MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases ...

1 week ago - GlobeNewsWire

Toxic stocks are vulnerable to external shocks, burdened with high debt and bound to result in loss for investors over time. Discard such stocks from your portfolio right away to avoid losses.

Other stocks mentioned: ATRO, MANU, TAST
1 week ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen business and prospects, resulting in its stock trading at inflated prices.

1 week ago - Business Wire

The big jump resulted from the company's partnership with Bharat Biotech to commercialize COVID-19 vaccine Covaxin.

1 week ago - The Motley Fool

New York, New York--(Newsfile Corp. - July 13, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advise...

1 week ago - Newsfile Corp

SAN DIEGO, July 12, 2021 /PRNewswire/ -- The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 193...

1 week ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that th...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 202...

1 week ago - Newsfile Corp

While the Delta variant Covid-19 strain threatens the population, OCGN stock investors can count on Ocugen to advance its vaccine candidate. The post Ocugen's Recent Vaccine Efficacy Results Should Have...

1 week ago - InvestorPlace

NEW YORK, July 10, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10,...

2 weeks ago - PRNewsWire

Investors may be getting concerned about how long it may take for COVID-19 vaccine Covaxin to get approved.

2 weeks ago - The Motley Fool

Los Angeles, California--(Newsfile Corp. - July 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...

2 weeks ago - Newsfile Corp

Stock markets moved slightly higher despite general worries.

Other stocks mentioned: BNTX, INO, MRNA, NVAX
2 weeks ago - The Motley Fool

BENSALEM, Pa., July 7, 2021 /PRNewswire/ --Law Offices of Howard G.

2 weeks ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - July 7, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen"...

2 weeks ago - Newsfile Corp

Phase 3 data on Covaxin wasn't outstanding, and there are indications that demand for additional vaccines in the U.S. and Canada will be low for some time. OCGN remains a good stock to short.

2 weeks ago - InvestorPlace

These seven meme stocks to buy could be good picks for July as investor interest in these high-risk, high-return plays continues to grow. The post 7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential ...

Other stocks mentioned: CLOV, CRSR, LFMD, NOK, BUZZ, FOMO
2 weeks ago - InvestorPlace

Ocugen Inc. (NASDAQ: OCGN) shares traded higher Tuesday after the company announced that its coronavirus vaccine co-development partner Bharat Biotech reported Phase 3 results demonstrating 77.8% protec...

2 weeks ago - Benzinga

OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward. The post 3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory appeared fi...

2 weeks ago - InvestorPlace

Los Angeles, California--(Newsfile Corp. - July 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...

2 weeks ago - Newsfile Corp

Ocugen's Indian vaccine development partner reported better-than-expected results from its local Covid-19 vaccine trials. OCGN stock has been on a roller-coaster ride on every Covaxin rumor and news item.

2 weeks ago - InvestorPlace

Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada...

2 weeks ago - Benzinga

While the contrarian bullish argument for OCGN stock has picked up considerable chatter, this is an extremely risky trade. The post Don't Play the Ocugen Stock Short Squeeze Before You Read This Warning!

2 weeks ago - InvestorPlace

Ocugen was a penny stock is up 180% for the year.  But all good things must come to an end.

2 weeks ago - InvestorPlace

New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised ...

2 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 5, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocug...

2 weeks ago - Newsfile Corp

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

Other stocks mentioned: ATRS, GTBP, OBSV, ODT, PTN, SEEL
2 weeks ago - PennyStocks

Los Angeles, California--(Newsfile Corp. - July 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...

2 weeks ago - Newsfile Corp

It may equal some coronavirus vaccine revenue ahead.

3 weeks ago - The Motley Fool

MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to ...

3 weeks ago - GlobeNewsWire

About OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development st... [Read more...]

Industry
Biotechnology
CEO
Shankar Musunuri
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
OCGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Ocugen stock is "Buy." The 12-month stock price forecast is 5.38, which is a decrease of -22.48% from the latest price.

Price Target
$5.38
(-22.48% downside)
Analyst Consensus: Buy